POU class 6 homeobox 2Genealiases: RPF-1 · WT5 · WTSL
Q-omics provides the consensus-scored POU6F2 profile across patient tissues and cancer cell-line models. POU6F2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, POU6F2 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, POU6F2 RNA expression shows 15,486 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SCLC, KICH, and GBM as cancer lineages where POU6F2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POU6F2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POU6F2 survival associations across molecular data types. POU6F2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POU6F2 RNA expression–survival associations across cancer types. High POU6F2 expression shows unfavorable associations in STAD and KIRP, but favorable associations in SCLC, UCS, PAAD and ESCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for POU6F2 RNA expression.
This table summarizes POU6F2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for POU6F2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POU6F2 shows lower tumor expression in KICH and CHOL and higher tumor expression in HNSC, LUSC, LUAD and COAD. The KICH box plot shows higher POU6F2 RNA expression in normal versus tumor tissue (log2 FC = −0.178, t-test p < 0.001).
This table shows molecular features associated with POU6F2 in patient tissues and cancer cell lines. In patient samples, POU6F2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, POU6F2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
